New gout pill shows promise in large trial
Disease control
Completed
This Phase 3 study tested AR882, a drug designed to lower uric acid levels in people with gout. Over 800 participants took either a 50 mg or 75 mg dose of AR882 or a placebo daily for 12 months. The main goal was to see if AR882 could bring uric acid below 6 mg/dL at 6 months, wh…
Phase: PHASE3 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC